Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06520345 · ClinicalTrials.gov registry record · Phase 3
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
A Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 430
- Enrollment target
- 15
- Study locations
NCT06520345 is a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by Telix Pharmaceuticals (Innovations) Pty Limited. The registered enrollment target is 430 participants, above the 192-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (124% higher). The trial reports 15 study locations across 12 states.
The verdict
NCT06520345, a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 430 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Enzalutamide
- DRUG Abiraterone
- DRUG 177Lu-TLX591
Study Locations (15)
New South Wales
- Westmead Hospital - Sydney
- Nepean Hospital - Sydney
- Wollongong Hospital - Wollongong
Utah
- Intermountain Health - Murray
- Intermountain Health - Salt Lake City
California
- Chao Family Comprehensive Cancer Centre - Orange
Florida
- Biogenix Molecular LLC - Miami
Maryland
- United Theranostics - Glen Burnie
Nebraska
- XCancer Omaha - Omaha
New York
- Columbia University Herbert Irving Comphrensive Cancer Center - New York
Ohio
- University Hospital - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2024-07-26 |
| Est. Completion | 2030-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06520345
The ClinicalTrials.gov registry entry for NCT06520345 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 430 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 192-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (124% higher). The listed sponsor is Telix Pharmaceuticals (Innovations) Pty Limited, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Docetaxel is the first listed.
NCT06520345 reports 15 study locations spanning 12 distinct geographic areas - top geographies include New South Wales, Utah, California.
Frequently Asked Questions
What is clinical trial NCT06520345 about?
NCT06520345 is a clinical study titled "The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)". The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment
What is the current status of trial NCT06520345?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 430 participants. The study started on 2024-07-26. Estimated completion is 2030-12.
What conditions does trial NCT06520345 study?
This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.
What interventions are being tested in trial NCT06520345?
The interventions under investigation include: Docetaxel (DRUG), Enzalutamide (DRUG), Abiraterone (DRUG), 177Lu-TLX591 (DRUG).
Who is sponsoring clinical trial NCT06520345?
This trial is sponsored by Telix Pharmaceuticals (Innovations) Pty Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06520345 being conducted?
This trial has 15 study locations across California, Florida, Maryland, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castration-Resistant Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
RECRUITING · Phase 3
-
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
RECRUITING · Phase 3
-
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
RECRUITING · Phase 3
-
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
RECRUITING · Phase 3
-
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
ACTIVE NOT RECRUITING · Phase 3
-
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.